Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Kim (La Jolla, United States of America), K. Chin (Dallas, United States of America), V. Mclaughlin (Ann Arbor, United States of America), R. Restrepo-Jaramillo (Tampa, United States of America), Z. Safdar (Houston, United States of America), M. Brand (Allschwil, Switzerland), M. Flynn (South San Francisco, United States of America), S. Leroy (Allschwil, Switzerland), A. Morganti (Allschwil, Switzerland), R. Channick (Los Angeles, United States of America). Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS. 5457

Member's Comments

No comment yet.

Related content which might interest you: Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview Source: Eur Respir Rev 2012 21:223-233 Year: 2012 Efficacy and safety of tadalafil in portopulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension Source: Eur Respir J, 53 (1) 1801880; 10.1183/13993003.01880-2018 Year: 2019 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006 Portopulmonary hypertension Source: Virtual Congress 2021 – Pulmonary vascular diseases Year: 2021 Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017